The new funding from Business Finland comes on the heels of a successful financing round announced last week.
The funding will help Mobidiag scale up production of its Novodiag instruments and disposable cartridges, and improve its global sales and marketing activities.
Amplidiag CarbaR+MCR detects the main carbapenemase-producing organisms and colistin resistance markers. Novidiag Bacterial GE+ identifies the most common enteric pathogens.
The deal covers all Amplidiag tests and the Amplidiag Easyinstrument, and represents Mobidiag's entry into the Baltic region, a company executive said.
The test, designed to simultaneously detect diarrhea-causing enteric viruses using DNA extracted from a stool sample, includes norovirus GI, norovirus GII, and others.
PerkinElmer's subsidiary Wallac will now distribute the Amplidiag product line in Israel and in a number of countries in Africa.
The funding was supported by Finnish investment service company Kansalaisrahoitus Oy.
The deal covers Mobidiag's full line of Amplidiag tests for gastrointestinal infections, as well as the high-throughput Amplidiag Easy system.
The firm received the CE IVD mark for Amplidiag Easy, an automated system that enables nucleic acid extraction and PCR setup directly from stool samples.